title: Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability.
abstract: Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder caused by mutations in the SMN1 gene. The homologous copy (SMN2) is always present in SMA patients. SMN1 gene transcripts are usually full-length (FL), but exon 7 is spliced out in a high proportion of SMN2 transcripts (delta7) (Δ7). Advances in drug therapy for SMA have shown that an increase in SMN mRNA and protein levels can be achieved in vitro. We performed a systematic analysis of SMN expression in primary fibroblasts and EBV-transformed lymphoblasts from seven SMA patients with varying clinical severity and different SMN1 genotypes to determine expression differences in two accessible tissues (skin and blood). The basal expression of SMN mRNA FL and Δ7 in fibroblasts and lymphoblasts was analyzed by quantitative real-time PCR. The FL-SMN and FL/Δ7 SMN ratios were higher in control cells than in patients. Furthermore, we investigated the response of these cell lines to hydroxyurea, valproate and phenylbutyrate, drugs previously reported to upregulate SMN2. The response to treatments with these compounds was heterogeneous. We found both intra-patient and inter-patient variability even within haploidentical siblings, suggesting that tissue and individual factors may affect the response to these compounds. To optimize the stratification of patients in clinical trials, in vitro studies should be performed before enrolment so as to define each patient as a responder or non-responder to the compound under investigation.
authors: Department of Genetics and CIBERER U-705 ISCIII, Hospital de Santa Creu i Sant Pau, Barcelona, Spain.
authors: Eva
authors: E
authors: Also-Rallo
authors: Laura
authors: L
authors: Alías
authors: Rebeca
authors: R
authors: Martínez-Hernández
authors: Lidia
authors: L
authors: Caselles
authors: María J
authors: MJ
authors: Barceló
authors: Montserrat
authors: M
authors: Baiget
authors: Sara
authors: S
authors: Bernal
authors: Eduardo F
authors: EF
authors: Tizzano
references: Eur J Hum Genet. 2005 Feb;13(2):256-9
references: 15523494
references: Neuromuscul Disord. 1992;2(5-6):423-8
references: 1300191
references: Hum Genet. 2002 Mar;110(3):257-63
references: 11935338
references: Neurology. 2010 Dec 14;75(24):2190-7
references: 21172842
references: Hum Mol Genet. 1999 Jul;8(7):1177-83
references: 10369862
references: Toxicol Sci. 2009 Mar;108(1):132-48
references: 19136453
references: Hum Mol Genet. 2000 Jan 22;9(2):259-65
references: 10607836
references: Expert Opin Investig Drugs. 2002 Dec;11(12):1695-713
references: 12457432
references: Hum Mol Genet. 2009 Oct 1;18(19):3645-58
references: 19584083
references: Neurology. 2007 Feb 6;68(6):451-6
references: 17283322
references: Neurology. 2007 Jan 2;68(1):51-5
references: 17082463
references: Proc Natl Acad Sci U S A. 1999 May 25;96(11):6307-11
references: 10339583
references: J Med Genet. 2010 Sep;47(9):640-2
references: 20577007
references: Hum Mol Genet. 1997 Aug;6(8):1205-14
references: 9259265
references: Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9808-13
references: 11504946
references: Nat Genet. 1997 Jul;16(3):265-9
references: 9207792
references: Hum Mol Genet. 2003 Oct 1;12(19):2481-9
references: 12915451
references: Eur J Hum Genet. 1999 Apr;7(3):301-9
references: 10234506
references: Ann Neurol. 2006 Jun;59(6):970-5
references: 16607616
references: Immunopharmacology. 1980 Jun;2(3):233-45
references: 7002864
references: Nature. 2009 Jan 15;457(7227):277-80
references: 19098894
references: Chem Biol. 2002 Jan;9(1):3-16
references: 11841934
references: Nat Genet. 1995 Nov;11(3):335-7
references: 7581461
references: Mutat Res. 2003 Nov 27;532(1-2):205-13
references: 14643437
references: Ann Neurol. 2003 Nov;54(5):647-54
references: 14595654
references: J Neuropathol Exp Neurol. 2005 Mar;64(3):215-23
references: 15804053
references: Hum Mol Genet. 2005 May 1;14(9):1171-82
references: 15772088
references: FEBS Lett. 2001 Apr 20;495(1-2):31-8
references: 11322942
references: Eur J Hum Genet. 2010 Jan;18(1):52-8
references: 19603064
references: PLoS One. 2009;4(5):e5268
references: 19440247
references: Cell. 1995 Jan 13;80(1):155-65
references: 7813012
references: Hum Genet. 2009 Feb;125(1):29-39
references: 19050931
references: Hum Mol Genet. 2009 Jan 15;18(2):304-17
references: 18971205
references: Clin Cancer Res. 2000 Nov;6(11):4334-42
references: 11106251
references: Neurogenetics. 2011 Feb;12(1):19-24
references: 21174137
references: Ann Neurol. 2005 Aug;58(2):194-202
references: 16049920
references: Am J Hum Genet. 2002 Feb;70(2):358-68
references: 11791208
references: Adv Ther. 2008 Mar;25(3):274-9
references: 18345520
references: J Neurol. 2006 Jan;253(1):21-5
references: 15981080
references: Genomics. 1996 Mar 15;32(3):479-82
references: 8838816
references: J Pharmacol Exp Ther. 2000 Sep;294(3):941-7
references: 10945844
references: Hum Mutat. 2003 Aug;22(2):136-43
references: 12872254
references: Eur J Hum Genet. 2004 Jan;12(1):59-65
references: 14560316
references: J Neurol Sci. 2008 May 15;268(1-2):87-94
references: 18166199
references: Cell. 1997 May 2;89(3):325-8
references: 9150131
references: Hum Genet. 2003 Dec;114(1):11-21
references: 14520560
references: Biochem Biophys Res Commun. 1995 Aug 4;213(1):342-8
references: 7639755
references: Neurology. 2006 Apr 11;66(7):1067-73
references: 16481599